Concluding Remarks

LOGIN

REGISTER

SUBSCRIBE


Forgot your login? GET HELP

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

In closing, I would like to review the rationale for developing new atypical agents for antipsychotic pharmacotherapy and to summarize information presented at this symposium about the innovative drug olanzapine. Numerous reviews of the literature suggest that the typical antipsychotic medications are far from optimal in treating psychosis. For example, Goff and Shader1 reported that more than half of patients receiving such a drug do not respond optimally.

J Clin Psychiatry 1997;58(suppl 10):63–72